The first clinical results from the CHOP described treating CLL,91,92 while researchers at MSKCC reported outcomes for adult B-ALL.93,94 Notably, the CHOP trials utilized CD19 CAR-T cells designed with the 4-1BB co-stimulatory domain (CD19-BB-z), a construct initially introduced by Dr. Dario Campana and Dr. Chihaya Imai at St. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.